[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.167.137. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
June 9, 2010

Beyond Hemoglobin A1c—Need for Additional Markers of Risk for Diabetic Microvascular Complications

Author Affiliations

Author Affiliations: Division of Metabolism, Endocrinology, and Nutrition, School of Medicine, and Diabetes Care Center, University of Washington, Seattle (Dr Hirsch); and Diabetes Research Center and Departments of Medicine and Pathology, Albert Einstein College of Medicine, Bronx, New York (Dr Brownlee).

JAMA. 2010;303(22):2291-2292. doi:10.1001/jama.2010.785

In 1993, The Diabetes Control and Complications Trial1 demonstrated that intensive therapy lowered time-averaged blood glucose values (measured as hemoglobin A1C [HbA1C]) and significantly reduced development of microvascular complications in type 1 diabetes. For example, intensive therapy reduced the risk of sustained retinopathy progression by 73% compared with standard treatment. Such significant reductions led to the recommendation by professional societies that for microvascular disease prevention, the HbA1C goal for nonpregnant adults should be less than 7% or even less than 6.5% of total hemoglobin.

First Page Preview View Large
First page PDF preview
First page PDF preview
×